What Is Abbott Laboratories (ABT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Abbott Laboratories at its current price of $92.12. The composite intrinsic value is estimated at $85.72 (-6.9% average return), with 8 models flagging overvaluation risk. Model dispersion is worth noting: Markov DDM targets $361.42 (+292.4%), versus Dynamic NAV at $20.17 (-78.1%). This +370.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ABT?
13 of 13 models are currently active for ABT. Of these, 4 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates ABT's intrinsic value at $112.75, implying +22.4% upside from the current price. See which stocks rank higher →
How Does ABT Rank in Medical Devices?
Among 10 Medical Devices stocks, ABT ranks #1 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places ABT in the top tier.
Within the Medical Devices space, Abbott Laboratories competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ABT a Value Trap?
The Value Trap algorithm is not active for ABT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Abbott Laboratories. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Abbott Laboratories's fundamental quality profile registers 10.0/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +370.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ABT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ABT's 13 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad